Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.50−0.04 (-7.55%)
Close on Nov 18, 2026Market cap $2.09MP/E –Yield –
Valion Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Valion Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$14.67M. For fiscal 2025 it was -$7.04M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.04M | – |
| FY2024 | Dec 31, 2024 | -$5.73M | – |
| FY2023 | Dec 31, 2023 | -$8.63M | – |
| FY2022 | Dec 31, 2022 | -$8.93M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.34M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.31M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$889.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.37M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.87M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.46M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.52M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.75M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.17M | – |
See a number that looks wrong?